NASDAQ: XRTXXortx Therapeutics Inc Stock
$0.87-0.08 (-8.42%)
Updated Apr 21, 2025
XRTX Price
$0.87
Fair Value Price
$1.25
Market Cap
$3.03M
52 Week Low
$0.80
52 Week High
$3.24
P/E
-1.09x
P/B
1.31x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$2.30M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.23
Operating Cash Flow
-$3M
Beta
0.14
Next Earnings
May 14, 2025
Ex-Dividend
N/A
Next Dividend
N/A
XRTX Overview
XORTX Therapeutics Incorporated, a bio-pharmaceutical company, develops and commercializes therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It developed XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease, XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection by suppressing acute kidney injury and associated health consequences, and XRx-221, a xanthine oxidase inhibitor candidate for the treatment of diabetic nephropathy. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine XRTX's potential to beat the market
- XRTX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
XRTX
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important XRTX news, forecast changes, insider trades & much more!
XRTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how XRTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
XRTX ($0.87) is undervalued by 30.62% relative to our estimate of its Fair Value price of $1.25 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
XRTX ($0.87) is significantly undervalued by 30.62% relative to our estimate of its Fair Value price of $1.25 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
XRTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more XRTX due diligence checks available for Premium users.
Valuation
XRTX fair value
Fair Value of XRTX stock based on Discounted Cash Flow (DCF)
Price
$0.87
Fair Value
$1.25
Undervalued by
30.62%
XRTX ($0.87) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
XRTX ($0.87) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
XRTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
XRTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.09x
Industry
-184.27x
Market
27.14x
XRTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.31x
Industry
4.04x
XRTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
XRTX's financial health
Profit margin
Revenue
$0.0
Net Income
$85.1k
Profit Margin
0%
XRTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$2.8M
Liabilities
$526.4k
Debt to equity
0.23
XRTX's short-term assets ($1.86M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XRTX's short-term assets ($1.86M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XRTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
XRTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$615.6k
Investing
-$2.8k
Financing
$768.8k
XRTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
XRTX vs Biotech Stocks
Xortx Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.